In Depth 24 Jul 2024 Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market? Find out more about Pfizer’s GLP-1 candidate danuglipron, as the company aims to compete in the obesity market. July 24, 2024 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 25 Mar 2024 Beyond Wegovy: Could Novo Nordisk’s new experimental weight loss pill be even better? Discover how Novo Nordisk’s new experimental obesity pill, amycretin, could be even more efficient for weight loss than Wegovy. March 25, 2024 - 4 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 18 Jan 2024 GLP-1 agonists: what’s the hype about? GLP-1 agonists have been on the radar for a while to treat diabetes and obesity. And of late, there has been renewed interest in these drugs. January 18, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 4 Jan 2024 Can GLP-1 agonists, the miraculous obesity drugs, treat cardiovascular diseases? Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases. January 4, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Dec 2023 Wrapping up 2023: A recap of top biotech moments of this year 2023 has been an exciting year for the industry. Here are some of the most notable biotech developments in 2023. December 20, 2023 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Dec 2023 Nine biotech companies to watch in 2024 2024 is shaping up to be an exciting year for the industry. Discover nine biotech companies to keep an eye on in 2024. December 19, 2023 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 28 Sep 2023 Obesity drug success sparks biotech buying spree The last few months have seen the obesity drug market soar, after new weight loss and diabetes drugs like Novo Nordisk’s Wegovy and Ozempic took the world by storm with their incredible efficacy at inducing weight loss. These new drugs belong to a class of medications called GLP-1 analogs (or incretin-based therapies), which work by […] September 28, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2023 Fighting obesity with gene therapy Scientists from the University of Barcelona in Spain and the Physiopathology of Obesity and Nutrition Networking Biomedical Research Centre (CIBERobn) have designed a strategy to fight obesity and diabetes in mice through ex vivo gene therapy. The technique consists of implanting cells that have been manipulated and transformed in order to treat a disease. This […] June 1, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2023 Aspect and Novo Nordisk working on bioprinted tissue for diabetes and obesity Aspect Biosystems and Novo Nordisk A/S are set to collaborate on developing bioprinted tissue therapeutics to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect’s bioprinting technology and Novo Nordisk’s background in stem cell differentiation […] April 13, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Mar 2023 Gut microbiota to be harnessed as a tool to diagnose diseases A recent study at the University of Jyväskylä in Finland compared the gut microbiota and gut-derived metabolites between healthy controls and individuals with fatty liver. The results revealed that certain microbial metabolites are associated with liver fat content. The fact that the gut microbiota associates with many diseases has raised the hope that they could […] March 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Feb 2023 Resalis Therapeutics receives €10M to develop obesity and NAFLD treatment Resalis Therapeutics has completed a seed financing round of €10 million to establish a non-coding RNA (ncRNA)-based therapeutic approach for the treatment of metabolic diseases. The funding will support the finalization of IND-enabling studies for the Resalis Therapeutics’ lead program, RES-010, which Resalis will initially develop as a novel treatment for obesity and nonalcoholic fatty […] February 24, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2023 HKUMed develops nanoparticle-based targeted drug delivery system A research team from LKS Faculty of Medicine, the University of Hong Kong (HKUMed) has developed thyroid hormone (TH) – encapsulated nanoparticles modified with adipose-homing peptide, which selectively transport TH to adipose tissues. The researchers say this will advance the treatment of obesity-related medical complications with TH by overcoming its severe adverse effects caused by […] February 21, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email